治療晚期腎細胞癌之口服標靶治療藥物：Everolimus

Everolimus: The Oral Targeted Therapy Drugs for Treating Late-stage Renal Cell Carcinoma

蘇郁仁(Yu-Jen Su)

《腫瘤護理雜誌》 13卷1期 (2013/06) Pp. 21-25

https://doi.org/10.6880/TJON.201306_13(1).03

摘要

在台灣，腎細胞癌約占所有惡性腫瘤的3%，由於初期症狀不明顯，發現通常已是晚期，因而面臨無藥可用的窘境。以往治療大多以免疫療法為首選，但近來以分子標靶治療藥物治療腎臟癌已逐漸成形。Everolimus的作用機轉便是藉由抑制mTOR蛋白，進一步抑制腫瘤細胞的分化生長與血管新生。此藥物不良反應包括口腔潰瘍、感染、無力、疲勞、腹瀉、咳嗽等，期許可搭配不同作用機轉的藥物，以做為治療腎細胞癌的選擇。

關鍵字

腎細胞癌 ； 標靶藥物

並列摘要

Renal cell carcinoma is about 3% among all malignant tumors in Taiwan. Because the symptoms are not obvious during the early stage, but usually found at the late stage, and thus encounter the dilemma of no drugs available. Formerly, the treatment preferred using the immunotherapy. However, recently the treatment is inclined to use the molecular target therapy for late-stage renal cell carcinoma Everolimus, a mammalian target of rapamycin (mTOR) protein inhibitor, which further inhibit tumor cell growth and differentiation of angiogenesis, is the first choice. For the patients with hepatic function impairment, dosage adjustment is necessary. The common adverse drug reactions include mouth ulcers, infections, weakness, fatigue, diarrhea, and cough. The health care providers need to inform patients of the possible adverse drug reactions, and of the combined use with different mechanisms of action of the drugs.

並列關鍵字

renal cell carcinoma ； targeted therapy drugs ； everolimus